财务摘要(人民币亿元)截至 6 月 30日止年度2025年中期2024年中期变动收入58.5060.07- 2.61%毛利8.4810.03- 15.45%税前利润8.398.99-6.67%本公司拥有人应占净利润6.416.87- 6.70%每股基本盈利 (人民币元)0.140.15- 6.67%香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 中海石油化学股份有限公司(「中海石油化学」或「公司」，股份编号：3983) 公布截至2025年6月30日止日止半年度未经审计之业绩。2025年上半年公司实现收入人民币5,850百万元，同比微跌2.6%，本公司拥有人权益应占净利润为人民币641百万元，同比微跌6.7%。中海石油化学首席执行官饶仕才先生表示：「纵使面对外部环境复杂多变与内部结构调整压力，公司主要经营指标仍然完成良好。期内，公司继续强化安全生产管理，积极拓展市场与销售渠道，深化精益管理；同时，扎实推进稳增长、深改革、提效能各项工作。此外，公司坚持秉持绿色可持续发展理念，甲醇装置连续十四年获评石化联合会『能效领跑者』荣誉称号，合成氨装置连续六年蝉联氮肥协会『水效领跑者』 荣誉称号，并荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』，树立了可持续发展品牌标杆。」生产管理方面，公司持续强化生产经营管控与体系管理，深入践行绿色发展理念，安全生产形势总体平稳。期内，海南富岛甲醇产量与八所港累计吞吐量均创历史同期新高，华鹤煤化工化肥装置实现314天长周期运行，刷新自身纪录，生产指标表现亮眼。上半年，公司生产尿素96.8万吨、甲醇78.1万吨、磷肥及复合肥45.0万吨、丙烯腈系列产品13.2万吨。销售管理方面，面对复杂多变的市场形势，公司持续深化市场研判，紧贴市场精准定价。通过固化产销协同周例会机制，优化储运衔接，保障产品高效流通。同时加大出口创效力度，全面推进拓市增效。上半年，公司销售尿素99.6万吨、甲醇72.6万吨、磷肥及复合肥38.6万吨、丙烯腈系列产品12.7万吨。绿色发展方面，上半年公司加速推进重点项目落地，成功产出以城市垃圾为原料的国内首吨绿色甲醇，并获得国际可持续发展和碳认证（ISCC）。该产品成功应用于国产双燃料船舶，实现了国内绿色甲醇首次加注。此外，公司实现监测数据统一接入环保资讯系统，污染物排放连续三年100%达标，环保污染事故事件保持为零。其中，大峪口化工磷石膏综合利用率由61.15%提升至73.09%，超额完成指标要求。展望2025下半年，尿素仍处于产能扩张周期，市场整体将延续「供大于求」格局，三季度受出口窗口期与农需支撑迭加影响，需求较强;进入四季度后，新增产能释放与需求转淡形成共振，价格预计持续承压。磷酸一铵价格或呈高位窄幅震荡态势，一方面原料成本支撑强劲，另一方面需求端亦有利好因素加持。磷酸二铵市场预计维持稳中整理节奏，三季度国内秋储与出口需求共振，整体需求旺盛，价格将保持平稳运行;四季度磷肥需求预计整体回落，价格存在回调压力，但受成本端支撑，整体波动幅度将较为有限。预计下半年，甲醇供应延续宽松态势，受益于国内反内卷及煤制甲醇新建项目政策限制，供需结构有望改善，下游需求或呈阶段性回暖，市场整体走势以震荡为主。丙烯腈方面，供过于求的格局预计将进一步加剧，丙烯腈价格若要出现好转，需依赖国内主流企业降低装置负荷。公司首席执行官饶仕才先生表示：「2025年下半年，公司将聚焦完善设备管理体系，保障装置安全平稳运行，夯实本质安全基础；同时着力打造品质定位，抓好拓市拓销，提升营销创效能力。此外，公司将推进『人工智慧+』行动，加速数智技术与实体经济的深度融合，推动富碳天然气利用重点项目研究及强化传播矩阵管理，持续提升品牌价值。」有关中海石油化学股份有限公司中海石油化学股份有限公司(「中海石油化学」)是专门从事化肥及相关化工产品开发、生产及销售的上市企业，是化肥产能及产量最大的中央企业，为从事石油和天然气勘探、开发、生产及销售的中国海洋石油集团有限公司之子公司。中海石油化学于2006年9月29日在香港联合交易所主板挂牌上市，股份编号：3983。公司现有生产设施位于中国海南、湖北及黑龙江，总设计年产能达184万吨尿素、130万吨磷复肥(磷酸一铵、磷酸二铵和复合肥)、140万吨甲醇、20万吨丙烯腈及7万吨MMA，公司并拥有位于海南省东方市的设计年吞吐能力为1,828万吨的深水港口。中海石油化学的企业品牌价值持续提升，2025年达72.58亿元，创历史新高。2025年，中海石油化学荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』。如欲查询更多公司资料，请浏览公司网站 www.chinabluechem.com.cn。 Copyright 2025 亚太商讯 via SeaPRwire.com.

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.